Skip to main content
SpringerLink
Log in

Herbs and Other Botanicals in Cancer Patient Care

  • Complementary and Alternative Therapies in Oncology
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Non-prescription herbal remedies are commonly used by cancer patients in efforts to control their disease or to manage symptoms associated with cancer and cancer treatments. We address the issues surrounding the use of herbs, herbal compounds, and other botanical agents in the oncology context. Botanicals are biologically active agents that can be useful under appropriate circumstances, but they may be counterproductive when used by patients on chemotherapy or on other prescription medications. Herbs and other botanical agents, despite common public belief, are not benign. They should be understood as unrefined pharmaceuticals, with the capacity to produce physiologic change for better or worse. Indeed, many prescription drugs, chemotherapeutic agents among them, were derived from plants and other natural agents, and the search for additional constituents of plants, animals, and minerals for use as pharmaceutical agents remains an active effort on many fronts. Cautions, appropriate application, and potential utility of botanical agents are discussed below, and sources of reliable information are provided.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: •Of importance

  1. Barnes PM, Powell-Griner E, McFann K, Nahin RL. Complementary and alternative medicine use among adults: United States, 2002. Adv Data 2004,343:1–19

    PubMed  Google Scholar 

  2. Correa-Velez I, Clavarino A, Eastwood H. Surviving, relieving, repairing, and boosting up: reasons for using complementary/alternative medicine among patients with advanced cancer: a thematic analysis. J Palliat Med 2005,8(5):953–961. doi:10.1089/jpm.2005.8.953

    Article  PubMed  Google Scholar 

  3. Gupta D, Lis CG, Birdsall TC, Grutsch JF. The use of dietary supplements in a community hospital comprehensive cancer center: implications for conventional cancer care. Support Care Cancer 2005,13(11):912–919. doi:10.1007/s00520-005-0820-9

    Article  PubMed  Google Scholar 

  4. Evans M, Shaw A, Thompson EA, et al. Decisions to use complementary and alternative medicine (CAM) by male cancer patients: information-seeking roles and types of evidence used. BMC Complement Altern Med 2007,7:25. doi:10.1186/1472-6882-7-25

    Article  PubMed  Google Scholar 

This paper describes well the reasons cancer patients use CAM.

  1. Verhoef MJ, Balneaves LG, Boon HS, Vroegindewey A. Reasons for and characteristics associated with complementary and alternative medicine use among adult cancer patients: a systematic review. Integr Cancer Ther 2005,4(4):274–286. doi:10.1177/1534735405282361

    Article  PubMed  Google Scholar 

  2. Meijerman I, Beijnen JH, Schellens JH. Herb-drug interactions in oncology: focus on mechanisms of induction. Oncologist 2006,11(7):742–752. doi:10.1634/theoncologist.11-7-742

    Article  CAS  PubMed  Google Scholar 

This article gives an overview of herb-drug interactions.

  1. Yeung KS, Gubili J. Clinical guide to herb-drug interactions in oncology. J Soc Integr Oncol 2007,5(3):113–117. doi:10.2310/7200.2007.008

    Article  PubMed  Google Scholar 

  2. Kasper S, Anghelescu IG, Szegedi A, Dienel A, Kieser M. Superior efficacy of St John’s wort extract WS 5570 compared to placebo in patients with major depression: a randomized, double-blind, placebo-controlled, multi-center trial [ISRCTN77277298]. BMC Med 2006,4:14. doi:10.1186/1741-7015-4-14

    Article  PubMed  Google Scholar 

  3. Mathijssen RH, Verweij J, de Bruijn P, Loos WJ, Sparreboom A. Effects of St. John’s wort on irinotecan metabolism. J Natl Cancer Inst 2002,94(16):1247–1249

    CAS  PubMed  Google Scholar 

  4. Chu DT, Wong WL, Mavligit GM. Immunotherapy with Chinese medicinal herbs. II. Reversal of cyclophosphamide-induced immune suppression by administration of fractionated Astragalus membranaceus in vivo. J Clin Lab Immunol 1988,25(3):125–129

    CAS  PubMed  Google Scholar 

  5. Chu DT, Wong WL, Mavligit GM. Immunotherapy with Chinese medicinal herbs. I. Immune restoration of local xenogeneic graft-versus-host reaction in cancer patients by fractionated Astragalus membranaceus in vitro. J Clin Lab Immunol 1988,25(3):119–123

    CAS  PubMed  Google Scholar 

  6. Liu B, Edgerton S, Yang X, et al. Low-dose dietary phytoestrogen abrogates tamoxifen-associated mammary tumor prevention. Cancer Res. 2005,65(3):879–886. doi:10.1158/0008-5472.CAN-04-3714

    Article  CAS  PubMed  Google Scholar 

  7. USDA. Fresh Product Grading and Quality Certification. http://www.ams.usda.gov/fv/fpbgapghp.htm. Accessed Jan 29, 2008

  8. WHO. WHO guidelines on good agricultural and collection practices (GACP) for medicinal plants. http://whqlibdoc.who.int/publications/2003/9241546271.pdf. Accessed Jan 29, 2008

  9. EUROPAM. Guidelines for Good Agricultural Practice (GAP) of Medicinal and Aromatic Plants. Accessed on June 11, 2008. http://www.europam.net/GAP.htm. Accessed on June 11, 2008

  10. NCCAM. Interim Policy: Biologically Active Agents Used in Complementary and Alternative Medicine (CAM) and Placebo Materials http://grants.nih.gov/grants/guide/notice-files/NOT-AT-05-003.html. Accessed Jan 29, 2008

  11. CDER. Guidance for Industry-Botanical Drug Products. http://www.fda.gov/cder/index.html. Accessed Jan 29, 2008

  12. Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT statement. Ann Intern Med 2006,144(5):364–367

    PubMed  Google Scholar 

  13. Vickers A, Goyal N, Harland R, Rees R. Do certain countries produce only positive results? A systematic review of controlled trials. Control Clin Trials 1998,19(2):159–166. doi:10.1016/S0197-2456(97)00150-5

    Article  CAS  PubMed  Google Scholar 

  14. NIH. Clinical Trials. http://www.clinicaltrials.gov/. Accessed Jan 29, 2008

  15. Kulp KS, Montgomery JL, Nelson DO, et al. Essiac and Flor-Essence herbal tonics stimulate the in vitro growth of human breast cancer cells. Breast Cancer Res Treat 2006,98(3):249–259. doi:10.1007/s10549-005-9156-x

    Article  PubMed  Google Scholar 

  16. Niimoto M, Hattori T, Tamada R, Sugimachi K, Inokuchi K, Ogawa N. Postoperative adjuvant immunochemotherapy with mitomycin C, futraful and PSK for gastric cancer. An analysis of data on 579 patients followed for five years. Jpn J Surg 1988,18(6):681–686. doi:10.1007/BF02471530

    Article  CAS  PubMed  Google Scholar 

  17. Nakazato H, Koike A, Saji S, Ogawa N, Sakamoto J. Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer. Lancet 1994,343(8906):1122–1126. doi:10.1016/S0140-6736(94)90233-X

    Article  CAS  PubMed  Google Scholar 

  18. Ogoshi K, Satou H, Isono K, Mitomi T, Endoh M, Sugita M. Possible predictive markers of immunotherapy in esophageal cancer: retrospective analysis of a randomized study. The Cooperative Study Group for Esophageal Cancer in Japan. Cancer Invest 1995,13(4):363–369. doi:10.3109/07357909509031916

    Article  CAS  PubMed  Google Scholar 

  19. Torisu M, Hayashi Y, Ishimitsu T, et al. Significant prolongation of disease-free period gained by oral polysaccharide K (PSK) administration after curative surgical operation of colorectal cancer. Cancer Immunol Immunother 1990,31(5):261–268. doi:10.1007/BF01740932

    Article  CAS  PubMed  Google Scholar 

  20. Mitomi T, Tsuchiya S, Iijima N, et al. Randomized, controlled study on adjuvant immunochemotherapy with PSK in curatively resected colorectal cancer. The Cooperative Study Group of Surgical Adjuvant Immunochemotherapy for Cancer of Colon and Rectum (Kanagawa). Dis Colon Rectum 1992,35(2):123–130. doi:10.1007/BF02050666

    Article  CAS  PubMed  Google Scholar 

  21. Ohwada S, Kawate S, Ikeya T, et al. Adjuvant therapy with protein-bound polysaccharide K and tegafur uracil in patients with stage II or III colorectal cancer: randomized, controlled trial. Dis Colon Rectum 2003,46(8):1060–1068. doi:10.1007/s10350-004-7281-y

    Article  PubMed  Google Scholar 

  22. Ohwada S, Ikeya T, Yokomori T, et al. Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer: a randomised controlled study. Br J Cancer 2004,90(5):1003–1010. doi:10.1038/sj.bjc.6601619

    Article  CAS  PubMed  Google Scholar 

  23. Toi M, Hattori T, Akagi M, et al.: Randomized adjuvant trial to evaluate the addition of tamoxifen and PSK to chemotherapy in patients with primary breast cancer. 5-Year results from the Nishi-Nippon Group of the Adjuvant Chemoendocrine Therapy for Breast Cancer Organization. Cancer 1992,70(10):2475–483. doi :10.1002/1097-0142(19921115)70:10<2475::AID-CNCR2820701014>3.0.CO;2-P

  24. Iino Y, Yokoe T, Maemura M, et al. Immunochemotherapies versus chemotherapy as adjuvant treatment after curative resection of operable breast cancer. Anticancer Res 1995,15(6B):2907–2911

    CAS  PubMed  Google Scholar 

  25. Ohno R, Yamada K, Masaoka T, et al. A randomized trial of chemoimmunotherapy of acute nonlymphocytic leukemia in adults using a protein-bound polysaccharide preparation. Cancer Immunol Immunother 1984,18(3):149–154. doi:10.1007/BF00205503

    Article  CAS  PubMed  Google Scholar 

  26. Small EJ, Frohlich MW, Bok R, et al. Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer. J Clin Oncol 2000,18(21):3595–3603

    CAS  PubMed  Google Scholar 

  27. Pfeifer BL, Pirani JF, Hamann SR, Klippel KF. PC-SPES, a dietary supplement for the treatment of hormone-refractory prostate cancer. BJU Int 2000,85(4):481–485. doi:10.1046/j.1464-410x.2000.00476.x

    Article  CAS  PubMed  Google Scholar 

  28. Oh WK, George DJ, Hackmann K, Manola J, Kantoff PW. Activity of the herbal combination, PC-SPES, in the treatment of patients with androgen-independent prostate cancer. Urology 2001,57(1):122–126. doi:10.1016/S0090-4295(00)00986-9

    Article  CAS  PubMed  Google Scholar 

  29. Oh WK, Kantoff PW, Weinberg V, et al. Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer. J␣Clin Oncol 2004,22(18):3705–712. doi:10.1200/JCO.2004.10.195

  30. Shabbir M, Love J, Montgomery B. Phase I trial of PC-Spes2 in advanced hormone refractory prostate cancer. Oncol Rep 2008,19(3):831–835

    PubMed  Google Scholar 

  31. Yano H, Mizoguchi A, Fukuda K, et al. The herbal medicine sho-saiko-to inhibits proliferation of cancer cell lines by inducing apoptosis and arrest at the G0/G1 phase. Cancer Res 1994,54(2):448–454

    CAS  PubMed  Google Scholar 

  32. Oka H, Yamamoto S, Kuroki T, et al. Prospective study of chemoprevention of hepatocellular carcinoma with Sho-saiko-to (TJ-9). Cancer 1995,76(5):743–749. doi :10.1002/1097-0142(19950901)

    Article  CAS  PubMed  Google Scholar 

  33. Sun AS, Ostadal O, Ryznar V, et al. Phase I/II study of stage III and IV non-small cell lung cancer patients taking a specific dietary supplement. Nutr Cancer 1999,34(1):62–69. doi:10.1207/S15327914NC340109

    Article  CAS  PubMed  Google Scholar 

  34. Bayne CW, Donnelly F, Ross M, Habib FK. Serenoa repens (Permixon): a 5alpha-reductase types I and II inhibitor-new evidence in a coculture model of BPH. Prostate 1999,40(4):232–241. doi :10.1002/(SICI)1097-0045(19990901)40:4<232::AID-PROS4>3.0.CO;2-0

  35. Boyle P, Robertson C, Lowe F, Roehrborn C. Meta-analysis of clinical trials of permixon in the treatment of symptomatic benign prostatic hyperplasia. Urology 2000,55(4):533–539. doi:10.1016/S0090-4295(99)00593-2

    Article  CAS  PubMed  Google Scholar 

  36. Bent S, Kane C, Shinohara K, et al. Saw palmetto for benign prostatic hyperplasia. N Engl J Med 2006,354(6):557–566. doi:10.1056/NEJMoa053085

    Article  CAS  PubMed  Google Scholar 

  37. Rao AV, Ray MR, Rao LG. Lycopene. Adv Food Nutr Res 2006,51:99–164. doi:10.1016/S1043-4526(06)51002-2

    Article  CAS  PubMed  Google Scholar 

  38. Bertram JS. Carotenoids and gene regulation. Nutr Rev 1999,57(6):182–191

    Article  CAS  PubMed  Google Scholar 

  39. Dahan K, Fennal M, Kumar NB. Lycopene in the prevention of prostate cancer. J Soc Integr Oncol 2008,6(1):29–36

    CAS  PubMed  Google Scholar 

  40. Schwarz S, Obermuller-Jevic UC, Hellmis E, Koch W, Jacobi G, Biesalski HK. Lycopene inhibits disease progression in patients with benign prostate hyperplasia. J Nutr 2008,138(1):49–53

    CAS  PubMed  Google Scholar 

  41. Kucuk O, Sarkar FH, Sakr W, et al. Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy. Cancer Epidemiol Biomarkers Prev 2001,10(8):861–868

    CAS  PubMed  Google Scholar 

  42. Jatoi A, Burch P, Hillman D, et al. A tomato-based, lycopene-containing intervention for androgen-independent prostate cancer: results of a Phase II study from the North Central Cancer Treatment Group. Urology 2007,69(2):289–294. doi:10.1016/j.urology.2006.10.019

    Article  PubMed  Google Scholar 

  43. Nagata Y, Sonoda T, Mori M, et al. Dietary isoflavones may protect against prostate cancer in Japanese men. J Nutr 2007,137(8):1974–1979

    CAS  PubMed  Google Scholar 

  44. deVere White RW, Hackman RM, Soares SE, Beckett LA, Li Y, Sun B. Effects of a genistein-rich extract on PSA levels in men with a history of prostate cancer. Urology 2004,63(2):259–263. doi:10.1016/j.urology.2003.09.061

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Integrative Medicine Service, Memorial Sloan-Kettering Cancer Center, 1429 First Avenue, New York, NY, 10021, USA

    Barrie Cassileth MS, PhD, K. Simon Yeung PharmD, LAc & Jyothirmai Gubili MS

Authors
  1. Barrie Cassileth MS, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. Simon Yeung PharmD, LAc
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jyothirmai Gubili MS
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jyothirmai Gubili MS.

Additional information

Information similar to that included here was presented in the authors’ previous publications.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cassileth, B., Yeung, K.S. & Gubili, J. Herbs and Other Botanicals in Cancer Patient Care. Curr. Treat. Options in Oncol. 9, 109–116 (2008). https://doi.org/10.1007/s11864-008-0061-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-008-0061-5

Keywords

Search

Navigation